Search results for "Guidelines."

showing 10 items of 611 documents

Diagnostic approach to microcephaly in childhood: a two-center study and review of the literature.

2014

Aim: The aim of this study was to assess the diagnostic approach to microcephaly in childhood and to identify the prevalence of the various underlying causes/disease entities. Method: We conducted a retrospective study on a cohort of 680 children with microcephaly (399 males, 281 females; mean age at presentation 7-8mo, range 1mo-5y) from patients presenting to Charité - University Medicine Berlin (n=474) and University Hospital Dresden (n=206). Patient discharge letters were searched electronically to identify cases of microcephaly, and then the medical records of these patients were used to analyze parameters for distribution. Results: The putative aetiology for microcephaly was ascertain…

MalePediatricsmedicine.medical_specialtyMicrocephalyEye DiseasesGenetic counselingMedizinComorbidityGene mutationEpilepsyDevelopmental NeuroscienceGermanyIntellectual DisabilitymedicineHumansRetrospective StudiesEpilepsybusiness.industryInfantRetrospective cohort studymedicine.diseaseComorbidityChild PreschoolPediatrics Perinatology and Child HealthCohortPractice Guidelines as TopicEtiologyMicrocephalyFemaleNeurology (clinical)businessDevelopmental medicine and child neurology
researchProduct

Standardized weaning of infants <32 weeks of gestation from continuous positive airway pressure – a feasibility study

2015

The practice of weaning premature infants from continuous positive airway pressure (CPAP) varies considerably and is usually performed without written standards. In this study, the feasibility of a standardized weaning approach was evaluated. In a quasi-experimental design, data from a prospective, post-intervention cohort (n=41) were compared to data from a pre-intervention cohort (n=36). Standardized weaning was feasible but no significant differences in short-term respiratory outcomes were observed. Weaning from CPAP was achieved at 32.1 ± 1.6 (post-intervention) versus 32.5 ± 2.3 weeks (pre-intervention) postmenstrual age. More rigorous, large-scale clinical trials are necessary before …

MalePediatricsmedicine.medical_specialtyTime Factorsmedicine.medical_treatment03 medical and health sciences0302 clinical medicine030225 pediatricsmedicineHumansWeaning030212 general & internal medicineContinuous positive airway pressureContinuous Positive Airway Pressurebusiness.industryInfant NewbornPostmenstrual AgeInfantObstetrics and GynecologyEvidence-based medicineClinical trialPractice Guidelines as TopicPediatrics Perinatology and Child HealthCohortFeasibility StudiesGestationFemalebusinessVentilator WeaningInfant PrematureThe Journal of Maternal-Fetal & Neonatal Medicine
researchProduct

GOLD 2017 treatment pathways in ‘real life’: An analysis of the DACCORD observational study

2017

Abstract Introduction The 2017 update to the Global Initiative for Obstructive Lung Disease (GOLD) strategy document includes recommendations for treatment intensification or step-down in chronic obstructive pulmonary disease (COPD), although recognises that limited supporting information is available. DACCORD is an ongoing observational, non-interventional study, recruiting patients following COPD maintenance treatment change or initiation, a subset of whom were receiving a long-acting β2-agonist (LABA) plus a long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) on entry. Since there were no requirements in terms of prior medication (and no washout before commencing LABA/L…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationmedicine.drug_classMuscarinic AntagonistsQuinolonesMaintenance ChemotherapyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePharmacotherapyAdrenal Cortex HormonesGermanyInternal medicineAdministration InhalationmedicineHumansddc:610Longitudinal StudiesProspective Studies030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAgedCOPDbiologybusiness.industryDisease ManagementMiddle AgedLamabiology.organism_classificationmedicine.diseaseGlycopyrrolateObstructive lung diseaseDrug Combinations030228 respiratory systemIndansPractice Guidelines as TopicCritical PathwaysDisease ProgressionPhysical therapyIndacaterolCorticosteroidDrug Therapy CombinationFemaleObservational studybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory Medicine
researchProduct

Do GOLD stages of COPD severity really correspond to differences in health status?

2003

The purpose of this study was to assess whether different stages of chronic obstructive pulmonary disease (COPD) severity defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria correlate with meaningful differences in health status. A total of 381 COPD patients, aged 73+/-6 yrs, were classified in the five GOLD stages. Disease-specific (St George Respiratory Questionnaire (SGRQ)) and generic indexes of health status were measured in all patients. Multivariate analysis of covariance or Kruskal Wallis tests were used to compare health status indexes across the spectrum of GOLD stages of COPD severity. GOLD stages of COPD severity significantly differed…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisPulmonary diseaseGlobal Initiative for Chronic Obstructive Lung Disease guidelineshealth statusComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexelderlyHealth StatuPulmonary Disease Chronic ObstructiveSurveys and QuestionnairesInternal medicineSeverity of illnessChronic obstructive pulmonary disease; elderly; Global Initiative for Chronic Obstructive Lung Disease guidelines; health statusmedicineSurveys and QuestionnaireHumansStage (cooking)Multivariate AnalysiRespiratory Function TestAgedCOPDbusiness.industryKruskal–Wallis one-way analysis of varianceChronic obstructive pulmonary diseaseAged; Comorbidity; Female; Humans; Linear Models; Male; Multivariate Analysis; Pulmonary Disease Chronic Obstructive; Respiratory Function Tests; Surveys and Questionnaires; Health Status; Severity of Illness Indexmedicine.diseaseComorbidityObstructive lung diseaseRespiratory Function TestsMultivariate AnalysisLinear ModelsPhysical therapyLinear ModelFemalebusinessHumanEuropean Respiratory Journal
researchProduct

European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of …

2020

ObjectiveThe best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.DesignInternational multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed.Results30 394 patients from 27 European countries were eval…

MaleRegistrieProton Pump InhibitorPractice Patterns0302 clinical medicineClarithromycinProspective StudiesRegistriesPractice Patterns Physicians'[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybiologyGastroenterologyMiddle AgedAnti-Bacterial Agents3. Good healthEurope030220 oncology & carcinogenesisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugHumanAdultmedicine.medical_specialtyTRIPLE THERAPY ; QUADRUPLE THERAPY ; CONSENSUS ; INFECTION ; METAANALYSIS ; CLARITHROMYCIN ; GUIDELINES ; RESISTANCE ; ARTICLESettore MED/12 - GASTROENTEROLOGIAFirst lineHelicobacter Infections03 medical and health sciencesDrug TherapyInternal medicineAnti-Bacterial AgentmedicineHumansMedical prescriptionAdverse effectAgedPhysicians'Helicobacter pyloribusiness.industryhelicobacter pylori - treatmentProton Pump InhibitorsAmoxicillinHelicobacter pyloribiology.organism_classificationMetronidazoleProspective StudieConcomitanthelicobacter pyloribusinessHelicobacter Infection[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Under-prescription of statins in patients with non-alcoholic fatty liver disease

2017

Abstract Background and Aim Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders. Methods and Results Cardiovascular risk and LDL-C targets were defined according to ESC/EAS Guidelines in 605 conse…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Disease030204 cardiovascular system & hematologyEndocrinology0302 clinical medicineDrug PrescriptionNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseNutrition and DieteticPractice Patterns Physicians'Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedDiabetes and MetabolismCardiovascular DiseasesPractice Guidelines as TopicCohortUnder-prescriptionFemalelipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyGuideline AdherenceCardiology and Cardiovascular MedicineHumanAdultCardiovascular risk; Non-alcoholic fatty liver disease; Statins; Under-prescription; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyStatinmedicine.drug_classContext (language use)Health Services MisuseDrug Prescriptions03 medical and health sciencesInternal medicinemedicineHumansMedical prescriptionAgedDyslipidemiasCross-Sectional Studiebusiness.industryRisk FactorStatinsStatinnutritional and metabolic diseasesNon alcoholicBiomarkerCholesterol LDLCardiovascular riskmedicine.diseaseCross-Sectional StudiesDyslipidemiaPhysical therapyHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

2014

Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these clai…

MaleSettore MED/09 - Medicina Internaendocrine system diseasesHSM MEDHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsAnticholesteremic Agents/adverse effectsMedizin1567-5688ComorbidityType 2 diabetesPharmacologyDiabeteHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageCardiovascularFasting/bloodCohort StudiesRisk FactorsAnticholesteremic Agents/administration & dosageDiabetes Mellitus Type 2/prevention & controlMulticenter Studies as TopicMedicineT2DDiabetisAnticholesteremic AgentsDiabetesHemoglobin A Glycosylated/analysisFastingGeneral MedicineMiddle AgedDiabetogenicityCVDClinical PracticeObservational Studies as TopicCholesterol LDL/bloodCardiovascular DiseasesPractice Guidelines as Topiclipids (amino acids peptides and proteins)Disease SusceptibilityCardiology and Cardiovascular MedicineRisk assessmentCardiovascular Diseases/prevention & controlCohort studyAdultmedicine.medical_specialtyStatinHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic usemedicine.drug_classAnticholesteremic Agents/therapeutic useHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyDiabetes Mellitus Type 2/etiologyRisk AssessmentMulticenter Studies as Topic/statistics & numerical dataPrediabetic StateMeta-Analysis as TopicDiabetes mellitusInternal MedicineHumansIntensive care medicinePrediabetic State/epidemiologyGlycated HemoglobinStatins; Diabetes; Diabetogenicity; T2D; Cardiovascular; CVDbusiness.industryCardiovascular Diseases/epidemiologyStatinsStatinnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseComorbidityAnticholesteremic Agents/pharmacologyDiabetes Mellitus Type 2/epidemiologyDiabetes Mellitus Type 2Estatines (Medicaments cardiovasculars)Observational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessObservational Study as TopicForecasting
researchProduct

DNA Commission of the International Society of Forensic Genetics: recommendations on forensic analysis using Y-chromosome STRs

2001

During the past few years, the DNA Commission of the International Society of Forensic Genetics has published a series of documents providing guidelines and recommendations concerning the application of DNA polymorphisms to the problems of human identification. This latest report addresses a relatively new area - namely, Y-chromosome polymorphisms, with particular emphasis on short tandem repeats (STRs). This report addresses nomenclature, use of allelic ladders, population genetics and reporting methods.

MaleSocieties ScientificISFGDNA CommissionPopulationLibrary scienceGuidelines as TopicPaternityCommissionBiologySTRY chromosome01 natural sciencesPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineTerminology as TopicY ChromosomeHumans030216 legal & forensic medicineeducationY-chromosomeAlleles030304 developmental biologyGeneticsInternet0303 health scienceseducation.field_of_studyPolymorphism Genetic010401 analytical chemistryDna polymorphismInternational AgenciesChromosome MappingDNAForensic MedicineSettore MED/43 - MEDICINA LEGALE0104 chemical sciencesForensic scienceGenetics PopulationDatabases as TopicTandem Repeat SequencesMutationMicrosatelliteIdentification (biology)LawForensic geneticsInternational Journal of Legal Medicine
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: insights from Italian general practice

2018

Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Methods: Patients aged ≥18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein cholesterol (non-HDL-C) was assessed in those with available total cholesterol measurements. Index dates were defined as the last valid lipid measurement in 2015. Patients were hierarchically classified into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and secondary prevention), atheroscler…

MaleTime FactorsSettore MED/09 - Medicina InternaDatabases FactualGeneral PracticeFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; StatinMedicine030212 general & internal medicinePractice Patterns Physicians'StrokeAged 80 and overLipid MeasurementMiddle AgedCardiovascular diseaseNon-high-density lipoprotein cholesterolCholesterolTreatment OutcomeItalyCardiovascular DiseasesCohortPractice Guidelines as Topiclipids (amino acids peptides and proteins)FemaleGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeStatinCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; Statin; Cardiology and Cardiovascular Medicinemedicine.drug_classRisk Assessment03 medical and health sciencesDiabetes mellitusInternal medicineHumansLow-density lipoprotein cholesterolAgedDyslipidemiasRetrospective Studiesbusiness.industryPreventionStatinCholesterol LDLmedicine.diseaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkers
researchProduct